Sodium Zirconium Cyclosilicate

Summary

Sodium Zirconium Cyclosilicate (CHEMBL3301592) is an approved small molecule (ATC V03AE10); indicated across 2 conditions including heart failure.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V03AE10
• Indications: 2 conditions
• Clinical trials: 20

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3301592
Name	Sodium Zirconium Cyclosilicate
Type	Small molecule
Max phase	4
ATC	V03AE10

Also known as: Lokelma, Sodium zirconium cyclosilicate, UXSi-9, ZS, ZS-9, SODIUM ZIRCONIUM CYCLOSILICATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
heart failure	2	MONDO:0005252	EFO:0003144

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE3	10
PHASE4	5
PHASE2	3
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04063930	PHASE4	UNKNOWN	The Effect of Sodium Zirconium Cyclosilicate on Albuminuria in Patients With Type 2 Diabetes and Hyperkalemia
NCT04585542	PHASE4	TERMINATED	Comparison of Potassium Binders in the ER
NCT04676646	PHASE4	COMPLETED	Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
NCT05535920	PHASE4	COMPLETED	A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia
NCT06365684	PHASE4	UNKNOWN	Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4
NCT06578078	PHASE3	RECRUITING	A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients
NCT06578533	PHASE3	RECRUITING	Keeping RAASi Treatment With Optimal Potassium Control
NCT02088073	PHASE3	COMPLETED	Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.
NCT02107092	PHASE3	COMPLETED	Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.
NCT02163499	PHASE3	COMPLETED	Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months
NCT03528681	PHASE3	COMPLETED	A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.
NCT04217590	PHASE3	COMPLETED	Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
NCT04727528	PHASE3	TERMINATED	Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease
NCT05004363	PHASE3	COMPLETED	Lokelma for RAAS Maximisation in CKD & Heart Failure.
NCT05382988	PHASE3	COMPLETED	Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
NCT04789239	PHASE2	ACTIVE_NOT_RECRUITING	OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure
NCT03532009	PHASE2	TERMINATED	Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
NCT04983979	PHASE2	TERMINATED	The ORTIZ Study: Optimising RASi Therapy With SZC
NCT04788641	PHASE1	COMPLETED	Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects
NCT04207203	Not specified	COMPLETED	Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).